Tag Archives: north

Papillary thyroid carcinoma: New research

In the presentation “Impact of Radioactive Iodine on Survival in Papillary Thyroid Carcinoma,” Paritosh Suman, M.D. and colleagues from North Shore University Health System (Evanston, IL), explore the benefit of (RAI) treatment following surgery to remove the thyroid in patients with PTC, and whether survival benefit relates to tumor size. In a retrospective study of nearly 285,000 patients treated over 13 years, with a mean follow-up of 7 years, the authors found that 47% of patients had RAI therapy and it showed a small but statistically significant survival benefit regardless of the tumor size. Carrie Lubitz, M.D., M.P.H., Massachusetts General Hospital (Boston), and coauthors previously described a novel blood-based assay for detecting the V600E mutation in the BRAF gene in patients with melanoma…

Years after treatment for HER2-positve early stage breast cancer, trastuzumab continues to show life-altering benefit

They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone. These findings, published in the Journal of Clinical Oncology, demonstrate how important trastuzumab has been to the treatment of this form of breast cancer, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida…

Adenocarcinoma: UK tops global league table for gullet cancer in men

Rates of SCC have remained fairly stable or have even fallen over the past few years, but those of adenocarcinoma have risen, particularly in high income countries. In 2012, esophageal cancer was the eighth most common cancer worldwide. The researchers used data from Cancer Incidence in Five Continents volume 10 to calculate age, sex, and country specific proportions of the two types of esophageal cancer. These figures were then applied to IARC global data on the number of new esophageal cancer cases in 2012 (GLOBOCAN 2012), and age-standardised rates calculated. …

Bio-inspired ‘nano-cocoons’ offer targeted drug delivery against cancer cells

“This drug delivery system is DNA-based, which means it is biocompatible and less toxic to patients than systems that use synthetic materials,” says Dr. Zhen Gu, senior author of a paper on the work and an assistant professor in the joint biomedical engineering program at NC State and UNC Chapel Hill. …

Elevated cholesterol, triglycerides may increase risk for prostate cancer recurrence

“While laboratory studies support an important role for cholesterol in prostate cancer, population-based evidence linking cholesterol and prostate cancer is mixed,” said Emma Allott, PhD, postdoctoral associate at Duke University School of Medicine in Durham, North Carolina. “Understanding associations between obesity, cholesterol, and prostate cancer is important given that cholesterol levels are readily modifiable with diet and/or statin use, and could therefore have important, practical implications for prostate cancer prevention and treatment. “Our findings suggest that normalization, or even partial normalization, of serum lipid levels among men with dyslipidemia [abnormal lipid profile] may reduce the risk of prostate cancer recurrence,” said Allott. …

Elevated cholesterol, triglycerides may increase risk for prostate cancer recurrence — ScienceDaily

“While laboratory studies support an important role for cholesterol in prostate cancer, population-based evidence linking cholesterol and prostate cancer is mixed,” said Emma Allott, PhD, postdoctoral associate at Duke University School of Medicine in Durham, North Carolina. “Understanding associations between obesity, cholesterol, and prostate cancer is important given that cholesterol levels are readily modifiable with diet and/or statin use, and could therefore have important, practical implications for prostate cancer prevention and treatment. “Our findings suggest that normalization, or even partial normalization, of serum lipid levels among men with dyslipidemia [abnormal lipid profile] may reduce the risk of prostate cancer recurrence,” said Allott. Allott, Stephen Freedland, MD, associate professor of surgery at Duke University School of Medicine, and colleagues, analyzed data from 843 men who underwent radical prostatectomy after a prostate cancer diagnosis and who never took statins before surgery. …

New molecule fights oxidative stress; May lead to therapies for cancer and Alzheimer’s

“Oxidative stress can cause damage to the building blocks of a cell, resulting in excessive cell proliferation, in the case of cancer or cell death, in the case of neurodegenerative diseases like Parkinson’s,” said Mark Hannink, a professor in the Department of Biochemistry and an investigator at the Bond Life Sciences Center at MU. “Finding the right balance is like walking a tightrope; our work has focused on finding ways to keep oxidative stress at bay.” Hannink partnered with High Point Pharmaceuticals LLC, a North Carolina-based firm, to find the right combinations of molecules to create an effective drug that fights free radicals. Using tools developed in his lab, Hannink and Kim Jasmer, a graduate student in Hannink’s lab, analyzed a group of molecules developed by the pharmaceutical company that could be good candidates for treating oxidative stress…

Fertility preservation option for young boys with cancer

The research, conducted by the Medical Center’s Wake Forest Institute for Regenerative Medicine (WFIRM) under the direction of Anthony Atala, M.D., institute director, gives boys who have a high risk of becoming sterile the option to “bank” a small piece of testicular tissue prior to treatment. “The average survival rates for childhood cancer are around 80 percent, but a side effect of some treatments can be permanent sterility,” said Thomas W. McLean, M.D., a pediatric cancer specialist, who co-leads the experimental biological bank with Hooman Sadri-Ardekani, M.D., Ph.D., a male infertility specialist at WFIRM. …

Trastuzumab should remain as standard of care for HER2-positive breast cancer, trial suggests

This study, being presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, reveals that when used as a single HER2-targeted therapy in addition to standard chemotherapy, trastuzumab offers a better outcome than does lapatinib (Tykerb), says Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. …